Trials / Completed
CompletedNCT00126438
Meta-Iodobenzylguanidine (123I-mIBG) Scintigraphy Imaging in Patients With Heart Failure and Control Subjects Without Cardiovascular Disease
An Open-Label, Multicenter, Phase 3 Study Evaluating the Prognostic Usefulness of I-123 mIBG Scintigraphy for Identifying Subjects With Heart Failure Who Will Experience an Adverse Cardiac Event
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 515 (actual)
- Sponsor
- GE Healthcare · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The study is designed to study the utility of 123I-mIBG as a diagnostic imaging agent to predict cardiac outcome in subjects with heart failure and in comparison to subjects without cardiovascular disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 123I-mIBG (meta-iodobenzylguanidine) | Single Dose |
Timeline
- Start date
- 2005-07-01
- Primary completion
- 2008-07-01
- Completion
- 2008-09-01
- First posted
- 2005-08-04
- Last updated
- 2018-03-14
- Results posted
- 2017-05-05
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00126438. Inclusion in this directory is not an endorsement.